Ownership history in JOHNSON & JOHNSON · 18 quarters on record
This page tracks every 13F SEC filing in which JOHNSON & JOHNSON reported a position in PROTAGONIST THERAPEUTICS INC. (PTGX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | UNCHANGED | 2,449,183 | — | 0% | 38.57% | $213.9M | $87.34 |
| 2025 Q3 | UNCHANGED | 2,449,183 | — | 0% | 32.30% | $162.7M | $66.43 |
| 2025 Q2 | UNCHANGED | 2,449,183 | — | 0% | 40.83% | $136.4M | $55.27 |
| 2025 Q1 | UNCHANGED | 2,449,183 | — | 0% | 34.65% | $118.4M | $48.36 |
As of 2025 Q4 — sorted by position size